JOURNAL OF ADDICTIVE DISEASES, published by ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, serves as a pivotal platform for researchers, clinicians, and students in the realms of clinical psychology, psychiatry, and addiction studies. With a distinguished history dating back to its inception in 1991, this journal spans critical research developments with its current scope covering converged years from 2018 to 2024, ensuring a robust repository of knowledge. Notably, it holds a respectable impact factor and is categorized in Q2 quartiles across several disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health for 2023, reflecting its impactful contributions to the scientific community. Despite the journal not currently offering Open Access, it remains highly ranked, occupying positions in the top percentiles of Scopus rankings. This journal emphasizes the importance of disseminating high-quality research focused on addictive behaviors and diseases, thereby addressing vital clinical and public health challenges.

DRUGS-EDUCATION PREVENTION AND POLICY is a premier scholarly journal published by Taylor & Francis Ltd, focusing on the critical intersection of drug education, prevention strategies, and policy formulation. Established in 1994 and continuing through its converged years into 2024, this journal holds significant relevance within the health and social sciences fields, with commendable standings reflected in its 2023 category quartile rankings of Q2 in both Health (Social Science) and Medicine (Miscellaneous). With an impact ranking that places it in the 73rd and 67th percentiles respectively, it serves as an influential platform for researchers, professionals, and students to disseminate innovative research, case studies, and policy analyses. Those interested in the complexities of drug-related issues are encouraged to explore the insights provided by this journal, contributing to the ongoing discourse in effective prevention and education practices in the context of drug use and its social implications. Although access to articles is not open, the wealth of knowledge presented is invaluable for academia and policy formulation alike.

Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

JOURNAL OF PSYCHOACTIVE DRUGS, published by Routledge Journals, Taylor & Francis Ltd, stands as a leading resource in the fields of psychology and medicine, focusing on the intersection of psychoactive substances and their impact on human behavior. With an ISSN of 0279-1072 and E-ISSN 2159-9777, this esteemed journal has been a pivotal platform for rigorous research since its inception in 1967, contributing to the understanding of drug use, its societal implications, and therapeutic potentials. It currently holds a Q2 ranking in both the miscellaneous categories of Medicine and Psychology for 2023, reflecting its significant standing within academic circles. Moreover, its Scopus rankings place it at the 49th percentile in General Psychology and 101st in Medicine, underscoring its relevance in contemporary research. Although it is not available via Open Access, the journal maintains a commitment to advancing knowledge through its annual publications until 2024. JOURNAL OF PSYCHOACTIVE DRUGS is essential for researchers, professionals, and students seeking to explore the complexities of psychoactive substances and their effects in various contexts.

Drugs Habits and Social Policy is an esteemed academic journal published by Emerald Group Publishing Ltd that focuses on the intersection of drug habits and the evolving landscape of social policy. With an ISSN of 2752-6739 and E-ISSN of 2752-6747, this journal contributes significantly to the fields of Clinical Psychology, Health Policy, and Public Health, and is ranked in the Q3 category across multiple disciplines in the 2023 categorizations. Featuring research that spans from 2022 to 2024, the journal provides a platform for critical insights and evidence-based discussions that are essential for understanding the social implications of drug use. Despite its current quartile ranking, the journal aims to elevate discourse among researchers, professionals, and students alike, reinforcing its commitment to impactful scholarship that can inform policy and practice. The journal is based in the United Kingdom, with its operations housed at Floor 5, Northspring 21-23 Wellington Street, Leeds, W YORKSHIRE LS1 4DL, ENGLAND. As a pivotal resource in its field, Drugs Habits and Social Policy invites contributions that can shape the future of health policy and improve societal outcomes.

Suchttherapie, an esteemed journal published by GEORG THIEME VERLAG KG, serves as a critical platform within the fields of Applied Psychology and Psychiatry and Mental Health. Established in 2000 and continuing through 2024, this journal is committed to advancing the understanding and treatment of addiction and related psychological issues. Although it currently stands in the Q4 Quartile ranking and is categorized as low percentile in both Scopus Ranks and impact metrics, its significance lies in its dedication to disseminating cutting-edge research and clinical findings that contribute to the evolving landscape of therapeutic practices. Published in Germany, the journal facilitates unlimited access to the vital discourse surrounding mental health and addiction treatment, making it a valuable resource for researchers, professionals, and students alike seeking to enhance their knowledge and skills in this important area of study. As the field continues to grow, Suchttherapie plays a pivotal role in bridging practice with academic rigor, ensuring that readers remain informed on the latest methodologies and insights.

The Journal of Addictions Nursing, published by Lippincott Williams & Wilkins, serves as a pivotal resource in the field of psychiatric and mental health nursing. With an ISSN of 1088-4602 and an E-ISSN of 1548-7148, this esteemed journal has been dedicated to advancing the knowledge and practice of addiction nursing since its inception in 1989. As of 2023, it ranks in the Q3 category of psychiatry and mental health, highlighting its significance amidst its peers. The journal provides a platform for the dissemination of original research, reviews, and clinical practices that address the complexities of addiction treatment and care. While it currently does not offer open access options, its valuable insights are accessible to practitioners and researchers committed to improving patient outcomes. With content spanning from 1989 to 2024, the journal continues to shape the discourse in this vital area of nursing, making it an essential read for professionals and scholars aiming to stay at the forefront of addiction nursing and intervention strategies.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

NICOTINE & TOBACCO RESEARCH, published by Oxford University Press, is a leading journal dedicated to advancing the understanding of nicotine and tobacco-related issues through rigorous research and analysis. Established in 1999, this esteemed journal has become a critical resource for scholars and practitioners in the fields of public health, environmental, and occupational health, maintaining a prestigious Q1 classification in its category as of 2023. With an impressive ranking of 67 out of 665 in the Scopus database, placing it in the 90th percentile, it is recognized for its high-quality contributions that resonate with current global health challenges. Although open access options are not available, the journal’s articles are accessible to a broad audience, ensuring that cutting-edge research reaches those who need it most. As it looks toward 2024 and beyond, NICOTINE & TOBACCO RESEARCH remains committed to promoting innovative research that informs policies and practices aimed at reducing tobacco use and its associated harms, thus playing a pivotal role in enhancing public health worldwide.

International Journal of Drug Policy, published by Elsevier, stands as a crucial scholarly platform dedicated to advancing the field of drug policy research. With an impactful focus on health policy and medicine, this journal holds a prestigious Q1 ranking in both Health Policy and Medicine (miscellaneous) categories as of 2023, reflecting its high-quality contributions to the discourse surrounding drug use, regulation, and public health. Spanning publication from 1998 to 2024, the journal's rich archive of research serves as an essential resource for researchers, professionals, and students alike. While the journal is not open access, it provides invaluable insights and significant findings that drive policy-making decisions and foster evidence-based practices in drug management and health interventions. With a Scopus rank of #28 out of 310 in Health Policy and #55 out of 398 in Medicine (miscellaneous), the International Journal of Drug Policy is indispensable for those committed to exploring and understanding the complexities of drug-related issues on a global scale.